Pune-based pharma firm: branded generics, biosimilars & injectables across India, EU, Canada & EM markets
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 181 | 181 | 181 | 181 | 181 | 189 | 190 | 190 |
| Reserves | 1.7k | 2.1k | 1.5k | 1.7k | 1.8k | 2.8k | 4.6k | 3.5k |
| Borrowings | 1.2k | 1.7k | 1.6k | 1.8k | 1.6k | 857 | 1.7k | 1.6k |
| Other Liabilities | 713 | 897 | 1.0k | 1.0k | 1.2k | 1.5k | 3.0k | 1.6k |
| Total Liabilities | 3.9k | 4.9k | 4.3k | 4.6k | 4.8k | 5.4k | 9.4k | 6.9k |
| AssetsFixed Assets | 1.2k | 1.3k | 1.2k | 1.4k | 1.7k | 1.8k | 3.3k | 1.8k |
| CWIP | 326 | 192 | 239 | 253 | 106 | 99 | 144 | 110 |
| Investments | 408 | 864 | 563 | 690 | 684 | 678 | 42 | 1.4k |
| Other Assets | 2.0k | 2.5k | 2.4k | 2.2k | 2.2k | 2.9k | 5.9k | 3.6k |
| Total Assets | 3.9k | 4.9k | 4.3k | 4.6k | 4.8k | 5.4k | 9.4k | 6.9k |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
EMCURE · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.